Special Report: Preparing for Stage 1 of the FDA’s LDTs Final Rule
Considerations for addressing compliance with Stage 1 of the FDA’s lab-developed tests final rule
Practical, “What-to-Do” and “How-to-Do-It” Help to Comply with the Latest State & Federal Laws, Rules & Regulations that Affect Your Diagnostic Lab or Pathology Practice
Considerations for addressing compliance with Stage 1 of the FDA’s lab-developed tests final rule
Understanding the process and implementing proper procedures is the key to ensuring compliance when reporting such events
The CDC’s OneLab training initiative offers free courses, events, resources, and networking opportunities for clinical lab professionals
Recent enforcement actions involved usual targets such as COVID-19, genetic, and urine drug testing, but EKRA also made an appearance
How the current FDA AI/ML device regulations may be impeding innovation in the clinical lab
FDA seems determined to push ahead with final rule, regardless of CDRH director’s departure, hiring of replacement.
CEO Laurie Menser discusses the Association for Molecular Pathology’s court case against the FDA’s rule on laboratory-developed tests.
The most common AI compliance risk areas related to data security and patient privacy, and the current regulatory landscape
Though needed to protect data and patient privacy, some in the industry say that more flexibility is needed
Recent government efforts to address increased cyberattacks in the healthcare space, and how your lab could benefit
Though payers’ adoption of AI has made reimbursement more challenging for labs, providers can also use AI to address these issues